Page 20 - Compass Pathways News Today

These stocks are risky. But they just might deliver huge gains if analysts are right.

Transcranial magnetic stimulation is associated with reductions in both anxiety and depression scores in patients with both disorders, a large new analysis shows.

This article by James Hallifax was originally published on Microdose and appears here with permission. 2022 was a milestone year for th...

Ongoing studies point to legitimate uses for mushrooms, ketamine, LSD and other such street drugs to treat challenging mental health conditions.

Investegate announcements from COMPASS Pathways, COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP

Major positive shifts are happening, but the field faces new headwinds too.

Psychedelics stocks were buoyed on Thursday morning by the news that Colorado voters had approved a midterm election ballot measure that would legalize the...

The hallucinogen psilocybin in “magic mushrooms” as a treatment for severe depression is getting closer for approval.

As psychedelic therapy trials get bigger and the drugs become more accessible, researchers need to start talking about their potential adverse effects.

This study showed that participants' depressive symptoms were relieved by a single 25-mg dose of psilocybin.